Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07475507
Active, not recruiting Not applicable

Effect of PEEK and Titanium Framework Reinforcement on Marginal Bone Loss Around Implants Supporting a Fixed All-on-four Prosthesis in Completely Edentulous Mandibles

NCT07475507 · tracked via the Priya Life Science Egypt tracker
Sponsor
Cairo University
Phase
Not applicable
Started
2024-08-01
Last updated
2026-03-16

Condition(s) studied

ProsthodonticsImplants, DentalProsthesisBone Loss, Alveolar

Investigational drug(s) / intervention(s)

Titanium framework reinforced all on four prosthesisPEEK framework reinforced all on four prosthesis

Titanium framework reinforced all on four prosthesis: Titanium frameworks provided many advantages as their biocompatibility, corrosion resistance, relatively lower weight and high mechanical properties as well as avoiding the casting errors and technique sensitivity

PEEK framework reinforced all on four prosthesis: Fabricating a fixed prosthesis for patients with completely edentulous mandibles reinforced with PEEK

Study summary

A fixed all-on-four prosthesis will be constructed for the lower arch for each patient and the marginal bone loss will be evaluated at baseline, 3,6,9 and 12 months.

Eligibility

Sex
ALL
Min age
45 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Completely edentulous patients requesting a fixed, implant supported restoration. 2. Patients aged from 45 to 60, able to sign an informed consent will be considered eligible for this trial. 3. Implant sites must allow the placement of four implants. 4. Non- heavy Smokers will be included (smoking up to 10 cigarettes/day) 5. In case of post-extraction sites, they must have been healed for at least 3 months before being treated in the study. 6. Patients with no systemic condition that may interfere with implant placement (e.g., Immunosuppressed or immunocompromised patients, patients under treatment of intravenous amino-bisphosphonates) \- Exclusion Criteria: 1. Patients with poor oral hygiene and motivation. 2. Female patients taking any medical treatment for management of osteoporosis. 3. Drug abusers. 4. Psychiatric problems or unrealistic expectations. 5. Patients with active infection or inflammation in the planned implant area at the time of implant placement. 6. Immuno-compromised patients (Diabetic with HBA1C \> 7 or patients undergoing chemo or radiotherapy or bisphosphonates)

Primary outcome measure(s)

  • Marginal bone loss — 12 months at intervals (0,3,6,9and 12 months)
    Marginal bone loss around each dental implant using parallel technique in digital periodical radiographs which will be measured in mm from the crestal bone level at the implant platform.

Trial sites (1)

FacilityCityRegionStatus
Faculty of Dentistry, Cairo University Cairo Cairo Governorate

More Cairo University trials in Egypt

The Link Between Periodontitis, Smoking and Oral Cancer Starting soon
Treating Intrabony Defect With MINST VS MINST Extended PRF Recruiting
Respiratory Exercises Versus Deep Neck Flexor Training in Chronic Mechanical Neck Pain Recruiting
Integrating Aerobic, Respiratory, and Cognitive Training in Acute Heart Failure Starting soon
Preparation Time Of Bioflx Crowns Compared To Zirconia Crowns On Primary Molars Starting soon

Other trials for the same condition

3D Printing Orientation and Film Thickness for Maxillary Complete Dentures Recruiting
Outcomes of Ridge Splitting Versus Sausage Technique Recruiting
Assessment of Customized 3D Zirconium Versus Titanium Mesh for Anterior Maxillary Ridge Augmentation With Delayed Implant Placement Active, not recruiting
Evaluation of Bone Gain Using Customized 3D Zirconia Barrier Versus Titanium Mesh Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07475507 on ClinicalTrials.gov ↗ ← All trials in Egypt